Continual reassessment method vs. traditional empirically based design

Modifications motivated by phase i trials in pediatric oncology by the pediatric brain tumor consortium

Arzu Onar, Mehmet Kocak, James M. Boyett

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

In this article we provide additional support for the use of a model-based design in pediatric Phase I trials and present our modifications to the continual reassessment method (CRM), which were largely motivated by specific challenges we encountered in the context of the Pediatric Brain Tumor Consortium trials. We also summarize the results of our extensive simulations studying the operating characteristics of our modified approach and contrasting it to the empirically based traditional method (TM). Compared to the TM, our simulations indicate that the modified version of CRM is more accurate, exposes fewer patients to potentially toxic doses, and tends to require fewer patients. Further, the CRM-based MTD has a consistent definition across trials, which is important, especially in a consortium setting where multiple agents are being tested in studies that are often running simultaneously and accruing from the same patient population.

Original languageEnglish (US)
Pages (from-to)437-455
Number of pages19
JournalJournal of Biopharmaceutical Statistics
Volume19
Issue number3
DOIs
StatePublished - May 1 2009

Fingerprint

Continual Reassessment Method
Phase I Trial
Brain Tumor
Oncology
Pediatrics
Brain Neoplasms
Model-based Design
Operating Characteristics
Simulation Methods
Dose
Tend
Poisons
Design
Simulation
Population

All Science Journal Classification (ASJC) codes

  • Statistics and Probability
  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{3c7019a1510a47098fae5cf147d2aaf3,
title = "Continual reassessment method vs. traditional empirically based design: Modifications motivated by phase i trials in pediatric oncology by the pediatric brain tumor consortium",
abstract = "In this article we provide additional support for the use of a model-based design in pediatric Phase I trials and present our modifications to the continual reassessment method (CRM), which were largely motivated by specific challenges we encountered in the context of the Pediatric Brain Tumor Consortium trials. We also summarize the results of our extensive simulations studying the operating characteristics of our modified approach and contrasting it to the empirically based traditional method (TM). Compared to the TM, our simulations indicate that the modified version of CRM is more accurate, exposes fewer patients to potentially toxic doses, and tends to require fewer patients. Further, the CRM-based MTD has a consistent definition across trials, which is important, especially in a consortium setting where multiple agents are being tested in studies that are often running simultaneously and accruing from the same patient population.",
author = "Arzu Onar and Mehmet Kocak and Boyett, {James M.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1080/10543400902800486",
language = "English (US)",
volume = "19",
pages = "437--455",
journal = "Journal of Biopharmaceutical Statistics",
issn = "1054-3406",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Continual reassessment method vs. traditional empirically based design

T2 - Modifications motivated by phase i trials in pediatric oncology by the pediatric brain tumor consortium

AU - Onar, Arzu

AU - Kocak, Mehmet

AU - Boyett, James M.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - In this article we provide additional support for the use of a model-based design in pediatric Phase I trials and present our modifications to the continual reassessment method (CRM), which were largely motivated by specific challenges we encountered in the context of the Pediatric Brain Tumor Consortium trials. We also summarize the results of our extensive simulations studying the operating characteristics of our modified approach and contrasting it to the empirically based traditional method (TM). Compared to the TM, our simulations indicate that the modified version of CRM is more accurate, exposes fewer patients to potentially toxic doses, and tends to require fewer patients. Further, the CRM-based MTD has a consistent definition across trials, which is important, especially in a consortium setting where multiple agents are being tested in studies that are often running simultaneously and accruing from the same patient population.

AB - In this article we provide additional support for the use of a model-based design in pediatric Phase I trials and present our modifications to the continual reassessment method (CRM), which were largely motivated by specific challenges we encountered in the context of the Pediatric Brain Tumor Consortium trials. We also summarize the results of our extensive simulations studying the operating characteristics of our modified approach and contrasting it to the empirically based traditional method (TM). Compared to the TM, our simulations indicate that the modified version of CRM is more accurate, exposes fewer patients to potentially toxic doses, and tends to require fewer patients. Further, the CRM-based MTD has a consistent definition across trials, which is important, especially in a consortium setting where multiple agents are being tested in studies that are often running simultaneously and accruing from the same patient population.

UR - http://www.scopus.com/inward/record.url?scp=67651052151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651052151&partnerID=8YFLogxK

U2 - 10.1080/10543400902800486

DO - 10.1080/10543400902800486

M3 - Review article

VL - 19

SP - 437

EP - 455

JO - Journal of Biopharmaceutical Statistics

JF - Journal of Biopharmaceutical Statistics

SN - 1054-3406

IS - 3

ER -